Publicly available information continues to remain scarce regarding this month’s decision by the General Court of the EU to temporarily suspend the European Commission’s revocation of the EU conditional marketing approval for Ocaliva, Advanz Pharma’s rare liver disease drug.
Key Takeaways
- The General Court of the EU’s website still only provides limited information on Advanz Pharma v Commission (Case T-455/24)
The Pink Sheet’s search of the General Court’s website on 19 September found there was still only limited information available, such as the names of the parties – Advanz Pharma v
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?